Literature DB >> 32020965

Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis.

V Manu1, Tin Aung Hein2, Dibyajyoti Boruah3, V Srinivas4.   

Abstract

BACKGROUND: The aim of this study was to evaluate the expression of p53, p16, Wilms tumor gene (WT1), and Mindbomb E3 Ubiquitin Protein Ligase 1 (MIB-1) index by immunohistochemical (IHC) staining in benign, low-grade, and high-grade serous ovarian tumors.
METHODS: Forty-one cases of ovarian serous tumors were included in the study (benign serous tumor [n = 10], low-grade ovarian serous carcinoma [n = 8], and high-grade ovarian serous carcinoma [n = 23]). Expression of p53, p16, WT1, and MIB-1 by IHC was evaluated statistically with the grade of tumor. Semiquantitative scoring system for percentage (0-5) and intensity (1-3) of staining pattern was used to bring about objectivity.
RESULTS: p53, p16, and WT1 showed significantly higher staining scores in ovarian serous carcinoma group than in the benign group (p < 0.05). However, p16 score was not significant in benign versus low-grade tumors. In the carcinoma group, the high-grade serous tumors showed significantly higher staining scores of p53, p16, and WT1 than the low-grade serous tumors (p < 0.05). Papillary serous tumors had comparatively lower p53 and WT1 scores for the same grade of tumor. MIB-1 scores were not significant.
CONCLUSION: p53, p16, and WT1 are helpful for the subtyping of serous ovarian tumors as low grade and high grade. WT1 is helpful in establishing primary ovarian serous tumors. The combination of moderate-to-high p53 and WT1 scores provides a robust way of confirming high-grade tumors.
© 2018 Armed Forces Medical Services (AFMS).

Entities:  

Keywords:  Immunohistochemistry (IHC); Ovary; Serous carcinoma

Year:  2018        PMID: 32020965      PMCID: PMC6994772          DOI: 10.1016/j.mjafi.2018.06.014

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  19 in total

1.  TP53 Mutation Status of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma with a Wild-type p53 Immunostaining Pattern.

Authors:  Kiyong Na; Ji-Youn Sung; Hyun-Soo Kim
Journal:  Anticancer Res       Date:  2017-12       Impact factor: 2.480

2.  Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.

Authors:  Eliane Tabea Taube; Carsten Denkert; Jalid Sehouli; Catarina Alisa Kunze; Manfred Dietel; Ioana Braicu; Anne Letsch; Silvia Darb-Esfahani
Journal:  Gynecol Oncol       Date:  2015-12-22       Impact factor: 5.482

3.  Changing trends in incidence of ovarian cancer - the Indian scenario.

Authors:  Nandagudi Srinivasa Murthy; S Shalini; G Suman; Srekantaiah Pruthvish; Aleyamma Mathew
Journal:  Asian Pac J Cancer Prev       Date:  2009

4.  Diagnostic and Prognostic Significance of Ki-67 Immunohistochemical Expression in Surface Epithelial Ovarian Carcinoma.

Authors:  Asha Mahadevappa; Shruthi Mysore Krishna; Manjunath Gubbanna Vimala
Journal:  J Clin Diagn Res       Date:  2017-02-01

5.  Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

Authors:  Gad Singer; Robert Stöhr; Leslie Cope; Reiko Dehari; Arndt Hartmann; Deng-Fan Cao; Tian-Li Wang; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2005-02       Impact factor: 6.394

6.  The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.

Authors:  Ludmila Liliac; Maria Luisa Carcangiu; Silvana Canevari; Irina Draga Căruntu; Delia Gabriela Ciobanu Apostol; M Danciu; M Onofriescu; Cornelia Amălinei
Journal:  Rom J Morphol Embryol       Date:  2013       Impact factor: 1.033

Review 7.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

8.  Comparative analysis of Rb1, P16 and ER as diagnostic, prognostic and potential targets for therapeutic agents in ovarian epithelial tumors: an immunohistochemical study of 130 ovarian carcinomas.

Authors:  Donna Catherine Ferguson; Daniel Jerad Long; Megan Christine Smith; Laura Deeanne Craig-Owens; Julie Means; Oluwole Fadare; Mohamed Mokhtar Desouki
Journal:  J Ovarian Res       Date:  2015-06-05       Impact factor: 4.234

9.  Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.

Authors:  Martin Köbel; Anna M Piskorz; Sandra Lee; Shuhong Lui; Cecile LePage; Francesco Marass; Nitzan Rosenfeld; Anne-Marie Mes Masson; James D Brenton
Journal:  J Pathol Clin Res       Date:  2016-07-13

Review 10.  Gynecological cancers: A summary of published Indian data.

Authors:  Amita Maheshwari; Neha Kumar; Umesh Mahantshetty
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep
View more
  1 in total

1.  PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis.

Authors:  Bo Seong Yun; Seyeon Won; Ju-Hyun Kim; Nara Lee; Miseon Kim; Mi Kyoung Kim; Mi-La Kim; Yong Wook Jung; Ji Young Kim; Seok Ju Seong; Eunah Shin
Journal:  J Ovarian Res       Date:  2022-04-06       Impact factor: 4.234

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.